Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 358

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 358
---
 partnerships with clinical laboratories. These laboratories offer advanced diagnostic services to their customers, which include health system stakeholders, such as patients, providers, government agencies, pharmacies, and/or private health institutions. Patient samples, including blood, tissue biopsies, saliva, plasma or nucleic acids, are collected through these clinical laboratories and processed in our Argentine Wet -Labaccording to the specific analysis required. Our genetic tests are designed for high accuracy in detection and profiling, utilizing sophisticated bioinformatics tools to decipher complex genetic information, and provide a wide array of clinically actionable insights. To support our operations, we have an agreement with a medical geneticist specializing in oncology and clinical genomics who provides counseling and advisory services as needed. Under this agreement, the professional offers genetic counseling, internal support for accurate genetic reporting, participation in medical events to promote our services, guidance for distributors on appropriate genetic tests, communication of results in an accessible manner, and collaboration in developing new services and scientific publications. The original contract was signed on June1, 2023, for one year and was later amended to extend its term through April1, 2025, with the possibility of renewal by mutual agreement. Either party may terminate the contract early with 30 days’ notice, without penalty. The professional operates independently, may provide services to other clients, and must maintain professional secrecy and confidentiality. Compensation is provided monthly, with automatic adjustments aligned with healthcare sector agreements. 182 Reproductive Genetics: Non-Invasive Prenatal Testing (“NIPT”) We have developed a proprietary non -invasiveprenatal screening test which incorporates a proprietary developed bioinformatics pipeline to analyze fetal DNA from maternal blood samples. The test, which can be administered from nine weeks of pregnancy through birth, screens for common genetic alterations including Down, Edwards, and Patau syndromes, sex chromosome abnormalities, specific aneuploidies, and pathogenic microdeletions/microduplications that could result in a range of genetic disorders. Our NIPT also determines the sex of the fetus and is recommended for all pregnant women, regardless of age and/or risk. Oncology: Hereditary Cancer Test This genetic test is designed to detect inherited mutations linked to an increased risk of hereditary cancers, including breast, ovarian, pancreatic, gastric, uterine, prostate, and renal cancers. Utilizing a blood sample, the test evaluates 113 genes for germline mutations, somatic point mutations (“SNV”), indels, and copy number variants (“CNV”), providing insights that